Floatz logo

Umbilical Cord Blood-Derived Natural Killer Cells

B-Cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

317 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Umbilical Cord Blood-Derived Natural Killer Cells is also rated in:

CD19 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
follicular lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →